Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia

Completed · Phase 1

Conditions studied: Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia

In brief

The purpose of this study is to determine the safety and effectiveness of INNO-406 in adult patients with imatinib-resistant or intolerant Philadelphia chromosome-positive (Ph+) leukemias.

Key facts

Study ID

NCT00352677

Run by

CytRx

People needed

100

Starts

2006-07-01

Expected to finish

2008-05-01

Last updated by the study team

2009-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a confirmed diagnosis of Ph+ ALL or CML in chronic, accelerated, or blastic phases that are either resistant to or intolerant of imatinib therapy.
• Be ≥18 years old.
• Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2.
• Have an estimated life expectancy of ≥12 weeks.
• Be male or non-pregnant, non-lactating female. Patients who are fertile must agree to use an effective barrier method of contraception while on therapy and for 90 days following discontinuation of study drug.
• Have a negative serum or urine pregnancy test within 7 days prior to the first dose of study drug (if patient is a female of childbearing potential).
• Have acceptable pre-treatment clinical laboratory results.

You may not qualify if…

• Have received chemotherapy ≤1 week from the start of therapy, with the exception of hydroxyurea and corticosteroids.
• Have received imatinib ≤3 days prior to enrollment or have not recovered from side effects of imatinib therapy.
• Have impaired cardiac function.
• Have an active, uncontrolled systemic infection considered opportunistic, life-threatening, or clinically significant at the time of treatment.
• Have clinically significant acute or chronic liver or renal disease considered unrelated to tumor.
• Have impaired gastrointestinal function that may significantly alter drug absorption (e.g., uncontrolled vomiting, ulcerative colitis, malabsorption, or small bowel resection).
• Are pregnant or lactating.
• Have psychiatric disorder(s) that would interfere with consent, study participation, or follow-up.
• Have not recovered from acute toxicity of all previous therapy prior to enrollment.
• Have any other severe concurrent disease and/or uncontrolled medical conditions, which, in the judgment of the investigator, could predispose patients to unacceptable safety risks or compromise compliance with the protocol.
• Have a history of another primary malignancy that is currently clinically significant or requires active intervention.

Where it is running

• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Charite University of Medicine — Berlin, Germany
• Johann Wolfgang Goethe Universität — Frankfurt am Main, Germany
• University of Heidelberg Medical Clinic — Mannheim, Germany
• Chaim Sheba Medical Center — Tel Litwinsky, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.